Nectin-4 in bladder cancer: biology and predictive biomarker potential.
Roessler N, Miszczyk M, Berger W, Englinger B, Eckstein M, Shariat SF (2026)
Publication Type: Journal article, Review article
Publication year: 2026
Journal
Book Volume: 36
Pages Range: 119-122
Journal Issue: 1
DOI: 10.1097/MOU.0000000000001354
Abstract
PURPOSE OF REVIEW: This review aims to summarize the biology and clinical relevance of Nectin-4 in patients with advanced bladder cancer, with a focus on its role as a therapeutic target and predictive biomarker. RECENT FINDINGS: Nectin-4 is consistently overexpressed in advanced bladder cancer, facilitating tumor progression and survival signaling. Its cell surface localization makes it an ideal target for antibody-drug conjugates (ADCs), such as enfortumab vedotin, which has shown excellent efficacy in both first-line treatment, post platinum-based chemotherapy, and following immune checkpoint inhibitors. Recent insights highlight Nectin-4 as potential predictive biomarker and a target for advanced medical imaging strategies. Resistance mechanisms and new combination approaches are currently being investigated. SUMMARY: Nectin-4 is a key therapy target in patients with advanced bladder cancer, as demonstrated by the success of enfortumab vedotin. Emerging ADC technologies and Nectin-4-targeted imaging tools could improve efficacy and patient selection, redefining both diagnostic and therapeutic approaches.
Authors with CRIS profile
Involved external institutions
Austria (AT)How to cite
APA:
Roessler, N., Miszczyk, M., Berger, W., Englinger, B., Eckstein, M., & Shariat, S.F. (2026). Nectin-4 in bladder cancer: biology and predictive biomarker potential. Current Opinion in Urology, 36(1), 119-122. https://doi.org/10.1097/MOU.0000000000001354
MLA:
Roessler, Navid, et al. "Nectin-4 in bladder cancer: biology and predictive biomarker potential." Current Opinion in Urology 36.1 (2026): 119-122.
BibTeX: Download